Atabak Mokari - Mar 1, 2024 Form 4 Insider Report for CORCEPT THERAPEUTICS INC (CORT)

Role
Chief Financial Officer
Signature
/s/ Joseph Douglas Lyon, as attorney-in-fact for Atabak Mokari.
Stock symbol
CORT
Transactions as of
Mar 1, 2024
Transactions value $
$890
Form type
4
Date filed
3/5/2024, 09:03 PM
Previous filing
Feb 13, 2024
Next filing
Jun 5, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CORT Common Stock Tax liability -$12.4K -517 -5.78% $24.06 8.43K Mar 1, 2024 Direct F1, F2
transaction CORT Common Stock Award $13.3K +554 +6.57% $24.06 8.98K Mar 1, 2024 Direct F2, F3, F4
transaction CORT Common Stock Award $0 +554 +6.17% $0.00 9.54K Mar 1, 2024 Direct F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.
F2 Includes 1,651 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, and 508 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F3 The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2012 Incentive Award Plan on March 1, 2024.
F4 In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
F5 Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.